T cell-mimicking platelet-drug conjugates

[1]  K. Pantel,et al.  Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. , 2022, Cell reports.

[2]  A. Papa,et al.  Platelet cancer cell interplay as a new therapeutic target. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[3]  René P. M. Lafleur,et al.  Role of Molecular Interactions in Supramolecular Polypeptide-Polyphenol Networks for Engineering Functional Materials. , 2022, Journal of the American Chemical Society.

[4]  F. Castro-Giner,et al.  The metastatic spread of breast cancer accelerates during sleep , 2022, Nature.

[5]  H. Hess,et al.  ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack , 2022, Science.

[6]  C. June,et al.  Engineered cellular immunotherapies in cancer and beyond , 2022, Nature Medicine.

[7]  H. Urlaub,et al.  Identification of distinct cytotoxic granules as the origin of supramolecular attack particles in T lymphocytes , 2022, Nature communications.

[8]  Quanyin Hu,et al.  Engineered platelets: Advocates for tumor immunotherapy , 2021, Nano Today.

[9]  Zheng Gu,et al.  Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis , 2021, Nature Communications.

[10]  Quanyin Hu,et al.  Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets , 2021, Nature Biomedical Engineering.

[11]  D. Brooks,et al.  Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? , 2021, Molecular cancer.

[12]  Anuradha Singh,et al.  Heme Induced Platelet Mitochondrial Oxidant Production Regulates Thrombospondin-1 Release from Platelets , 2020 .

[13]  S. Mitragotri,et al.  Engineering of Living Cells with Polyphenol‐Functionalized Biologically Active Nanocomplexes , 2020, Advanced materials.

[14]  D. Davis,et al.  Synaptic secretion from human natural killer cells is diverse and includes supramolecular attack particles , 2020, Proceedings of the National Academy of Sciences.

[15]  Michael Loran Dustin,et al.  Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells , 2020, Science.

[16]  C. Mackall,et al.  The Emerging Landscape of Immune Cell Therapies , 2020, Cell.

[17]  Joseph J. Richardson,et al.  Polyphenol-Mediated Assembly of Proteins for Engineering Functional Materials. , 2020, Angewandte Chemie.

[18]  P. Timpson,et al.  Fluids and their mechanics in tumour transit: shaping metastasis , 2019, Nature Reviews Cancer.

[19]  D. Rogers,et al.  Electronic Circular Dichroism Spectroscopy of Proteins , 2019, Chem.

[20]  Quanyin Hu,et al.  Platelet for drug delivery. , 2019, Current opinion in biotechnology.

[21]  S. Massberg,et al.  Patrolling the vascular borders: platelets in immunity to infection and cancer , 2019, Nature Reviews Immunology.

[22]  K. Pantel,et al.  Liquid biopsy and minimal residual disease — latest advances and implications for cure , 2019, Nature Reviews Clinical Oncology.

[23]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[24]  A. Scott,et al.  Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases , 2019, Theranostics.

[25]  A. S. St. John,et al.  Adaptive immune responses to primary and secondary dengue virus infections , 2019, Nature Reviews Immunology.

[26]  Chen Jiang,et al.  Activated Platelets‐Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer , 2019, Advanced Functional Materials.

[27]  S. Vanharanta,et al.  Circulating Tumor Cells: Come Together, Right Now, Over Metastasis. , 2019, Cancer discovery.

[28]  G. Storm,et al.  Granzyme B‐loaded, cell‐selective penetrating and reduction‐responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Quanyin Hu,et al.  Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy , 2018, Nature Biomedical Engineering.

[30]  A. Sood,et al.  The Platelet Lifeline to Cancer: Challenges and Opportunities. , 2018, Cancer cell.

[31]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[32]  Zhen Gu,et al.  In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy , 2017, Nature Biomedical Engineering.

[33]  Joseph J. Richardson,et al.  Modular assembly of superstructures from polyphenol-functionalized building blocks. , 2016, Nature nanotechnology.

[34]  Sara A Abouelmagd,et al.  Tannic acid-mediated surface functionalization of polymeric nanoparticles. , 2016, ACS biomaterials science & engineering.

[35]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[36]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[37]  J. Liesveld,et al.  Genetic engineering of platelets to neutralize circulating tumor cells. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Zhen Gu,et al.  Anticancer Platelet‐Mimicking Nanovehicles , 2015, Advanced materials.

[39]  James C. Whisstock,et al.  Perforin and granzymes: function, dysfunction and human pathology , 2015, Nature Reviews Immunology.

[40]  R. Hynes,et al.  Platelets guide the formation of early metastatic niches , 2014, Proceedings of the National Academy of Sciences.

[41]  B. Chong,et al.  Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. , 2012, Cancer research.

[42]  J. Lieberman,et al.  Perforin pores in the endosomal membrane trigger release of endocytosed granzyme B to the cytosol of target cells , 2011, Nature Immunology.

[43]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[44]  J. Whisstock,et al.  The structural basis for membrane binding and pore formation by lymphocyte perforin , 2010, Nature.

[45]  D. Roberts,et al.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.

[46]  Mark J. Smyth,et al.  Perforin-mediated target-cell death and immune homeostasis , 2006, Nature Reviews Immunology.

[47]  Shu Shun Li,et al.  Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. , 2006, Blood.

[48]  J. Holgersson,et al.  T lymphocyte expression of thrombospondin‐1 and adhesion to extracellular matrix components , 2002, European journal of immunology.

[49]  Michael P. MacManus,et al.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? , 2017, Nature Reviews Clinical Oncology.

[50]  Pengcheng Bu,et al.  Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. , 2016, Biomaterials.